Clearmind Medicine announces the U.S. publication of a patent application for a combination of MDMA and N-acylethanolamines (notably palmitoylethanolamide, PEA) to treat PTSD, anxiety, and eating disorders, developed with NeuroThera Labs Inc.

The filing comes as the FDA released final guidance in mid-July 2026 on psychedelic drug development, explicitly including MDMA and outlining regulatory considerations for clinical investigations.

Embodiments described suggest PEA could boost MDMA’s potency, allow lower dosing, reduce side effects, and widen the therapeutic window, potentially strengthening clinical and commercial prospects.

The stock market gave a modest negative intraday reaction to the announcement, with CMND trading around $1.72 on elevated volume amid IP news and regulatory developments.

The Form 6-K includes the press release text and notes that the patent is not yet issued, outlining current status.

The release adds FAQs about the patent, potential benefits, portfolio details, and cites GlobeNewswire for the full press release.

Clearmind’s shares trade on Nasdaq under the ticker CMND.

The press release contains standard forward-looking statements regarding therapeutic benefits, safety, dosing, and regulatory pathways, with explicit risk disclosures as in SciSparc’s filings.

Key risks highlighted include patent validity, possibility that potency or tolerability is not enhanced, regulatory challenges, MDMA’s Schedule I status, funding needs, and reliance on third parties.

Forward-looking statements acknowledge that patent issuance is not guaranteed and benefits depend on future developments amid regulatory and clinical uncertainties.

Exhibit 99.1 provides background on the MDMA-N-acylethanolamines IP and its potential regulatory and market implications.

The press release underscores potential regulatory and development advantages from the FDA guidance and an expanded IP portfolio.